Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iberdomide - Bristol Myers Squibb

Next Previous
Drug Profile

Iberdomide - Bristol Myers Squibb

Alternative Names: BMS 986382; CC-220; IBER; ZENBEXUS

Latest Information Update: 18 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Bristol-Myers Squibb; Celgene Corporation; Emory University
  • Class Anti-inflammatories; Antineoplastics; Isoindoles; Piperidones; Skin disorder therapies; Small molecules
  • Mechanism of Action Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Multiple myeloma
  • Phase II Smoldering multiple myeloma
  • Phase I/II B-cell lymphoma
  • Phase I Lymphoma; Non-Hodgkin's lymphoma
  • Discontinued Atopic dermatitis; Cutaneous lupus erythematosus; Follicular lymphoma; Sarcoidosis; Systemic lupus erythematosus; Systemic scleroderma

Most Recent Events

  • 13 Aug 2026 Efficacy data from a phase III trial in Multiple myeloma released by Bristol-Myers Squibb
  • 13 Aug 2026 Registered for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO) - First global approval
  • 31 Jul 2026 Icahn School of Medicine at Mount Sinai plans an early phase I trial for Multiple myeloma (Second-line therapy or greater) in USA (PO, Capsule) in July 2026 (NCT07727668)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top